Stock Price, News, Quote and Profile of INHIBIKASE THERAPEUTICS INC(NASDAQ:IKT) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

INHIBIKASE THERAPEUTICS INC

NASDAQ:IKT (4/26/2024, 7:00:02 PM)

1.71

-0.19 (-10%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap11.08M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Inhibikase Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Atlanta, Georgia and currently employs 6 full-time employees. The company went IPO on 2020-12-23. Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm is focused on developing therapeutics for Parkinson's disease and related disorders. The Company’s multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The firm is also developing platform technologies for alternate ways to deliver protein kinase inhibitors in patients, which includes IkT-001Pro. IkT-001Pro is a prodrug of the anticancer agent imatinib mesylate, to treat stable phase chronic myelogenous leukemia (SP-CML). The Company’s RAMP drug discovery program used imatinib as a template to design and discover a family of novel chemical entities with high potency against c-Abl, leading to IkT-148009.